504 related articles for article (PubMed ID: 12414858)
1. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.
Yamazaki Y; Okazaki R; Shibata M; Hasegawa Y; Satoh K; Tajima T; Takeuchi Y; Fujita T; Nakahara K; Yamashita T; Fukumoto S
J Clin Endocrinol Metab; 2002 Nov; 87(11):4957-60. PubMed ID: 12414858
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.
Jonsson KB; Zahradnik R; Larsson T; White KE; Sugimoto T; Imanishi Y; Yamamoto T; Hampson G; Koshiyama H; Ljunggren O; Oba K; Yang IM; Miyauchi A; Econs MJ; Lavigne J; Jüppner H
N Engl J Med; 2003 Apr; 348(17):1656-63. PubMed ID: 12711740
[TBL] [Abstract][Full Text] [Related]
3. Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia.
Xia WB; Jiang Y; Li M; Xing XP; Wang O; Hu YY; Zhang HB; Liu HC; Meng XW; Zhou XY
Chin Med J (Engl); 2010 May; 123(9):1158-62. PubMed ID: 20529556
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of assay system for fibroblast growth factor (FGF)-23 and pathophysiological roles of FGF-23 in the development of hypophosphatemic diseases].
Fukumoto S; Nakahara K
Rinsho Byori; 2004 Jan; 52(1):51-4. PubMed ID: 14968560
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two assays for fibroblast growth factor (FGF)-23.
Ito N; Fukumoto S; Takeuchi Y; Yasuda T; Hasegawa Y; Takemoto F; Tajima T; Dobashi K; Yamazaki Y; Yamashita T; Fujita T
J Bone Miner Metab; 2005; 23(6):435-40. PubMed ID: 16261449
[TBL] [Abstract][Full Text] [Related]
6. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo.
Shimada T; Muto T; Urakawa I; Yoneya T; Yamazaki Y; Okawa K; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Endocrinology; 2002 Aug; 143(8):3179-82. PubMed ID: 12130585
[TBL] [Abstract][Full Text] [Related]
7. Serum FGF23 levels in normal and disordered phosphorus homeostasis.
Weber TJ; Liu S; Indridason OS; Quarles LD
J Bone Miner Res; 2003 Jul; 18(7):1227-34. PubMed ID: 12854832
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor-23 is the phosphaturic factor in tumor-induced osteomalacia and may be phosphatonin.
Fukumoto S; Yamashita T
Curr Opin Nephrol Hypertens; 2002 Jul; 11(4):385-9. PubMed ID: 12105387
[TBL] [Abstract][Full Text] [Related]
9. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia.
Takeuchi Y; Suzuki H; Ogura S; Imai R; Yamazaki Y; Yamashita T; Miyamoto Y; Okazaki H; Nakamura K; Nakahara K; Fukumoto S; Fujita T
J Clin Endocrinol Metab; 2004 Aug; 89(8):3979-82. PubMed ID: 15292336
[TBL] [Abstract][Full Text] [Related]
10. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of bone markers in hypophosphatemic rickets/osteomalacia.
Nagata Y; Imanishi Y; Ishii A; Kurajoh M; Motoyama K; Morioka T; Naka H; Mori K; Miki T; Emoto M; Inaba M
Endocrine; 2011 Oct; 40(2):315-7. PubMed ID: 21822687
[TBL] [Abstract][Full Text] [Related]
12. Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia.
Lyles KW; Clark AG; Drezner MK
Calcif Tissue Int; 1982 Mar; 34(2):125-30. PubMed ID: 6282408
[TBL] [Abstract][Full Text] [Related]
13. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
[TBL] [Abstract][Full Text] [Related]
14. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets.
Imel EA; Hui SL; Econs MJ
J Bone Miner Res; 2007 Apr; 22(4):520-6. PubMed ID: 17227222
[TBL] [Abstract][Full Text] [Related]
15. The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets.
Lyles KW; Burkes EJ; McNamara CR; Harrelson JM; Pickett JP; Drezner MK
J Clin Endocrinol Metab; 1985 Apr; 60(4):711-7. PubMed ID: 4038714
[TBL] [Abstract][Full Text] [Related]
16. Resolution of severe, adolescent-onset hypophosphatemic rickets following resection of an FGF-23-producing tumour of the distal ulna.
Ward LM; Rauch F; White KE; Filler G; Matzinger MA; Letts M; Travers R; Econs MJ; Glorieux FH
Bone; 2004 May; 34(5):905-11. PubMed ID: 15121023
[TBL] [Abstract][Full Text] [Related]
17. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
Bielesz B
Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
[TBL] [Abstract][Full Text] [Related]
18. New insights into phosphate homeostasis: fibroblast growth factor 23 and frizzled-related protein-4 are phosphaturic factors derived from tumors associated with osteomalacia.
Kumar R
Curr Opin Nephrol Hypertens; 2002 Sep; 11(5):547-53. PubMed ID: 12187320
[TBL] [Abstract][Full Text] [Related]
19. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice.
Sitara D; Razzaque MS; Hesse M; Yoganathan S; Taguchi T; Erben RG; Jüppner H; Lanske B
Matrix Biol; 2004 Nov; 23(7):421-32. PubMed ID: 15579309
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia.
Aono Y; Yamazaki Y; Yasutake J; Kawata T; Hasegawa H; Urakawa I; Fujita T; Wada M; Yamashita T; Fukumoto S; Shimada T
J Bone Miner Res; 2009 Nov; 24(11):1879-88. PubMed ID: 19419316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
